Taurine Supplement Tested for Blood Sugar in Type 2 Diabetes
Tests taurine, a supplement, in adults with type 2 diabetes against placebo.
Plain-language title generated from the registry record
Registry title: Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes
Key facts
- Where
- Porto Alegre, BrazilSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 80 years old?
Source: NCT04874012, who can take part
Where in Brazil
- Hospital de ClínicasPorto Alegre, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital de Clinicas de Porto Alegre
- Trial code
- NCT04874012
- Record updated
- 24 September 2026
- Original description
Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.Read full original descriptionShow less
Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial
Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.
Inclusion: Female and male individuals, with clinical diagnosis of DM2 for at least 6 months; Age over 30 years; BMC equal to or above 18.5 kg/m2, without weight change in the last 3 months; HbA1c between 7.5% and 10.5%.
Exclusion: Bariatric surgery; Chronic renal failure with glomerular filtration rate calculated by MDRD < 30 mL/h; Myocardial infarction in the last than 6 months; Use of herbal supplements, antioxidants, and multivitamins in the last 3 months; Pregnancy or lactation; Current neoplasia; Chronic use of glucocorticoids.